Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.


This website is intended for US Healthcare Professionals

Simple, once-daily dosing1

30 mcg administered orally once daily at bedtime

  • Before initiating treatment, ensure serum calcium is <9.8 mg/dL
  • Instruct patients to swallow Rayaldee capsules whole
  • Instruct patients to skip a missed dose and to resume taking the medicine at the next regularly scheduled time. Do not administer an extra dose